65,437 trials
Pain
Primary: Pain Area Under the Curve 0-8h (AUC0-8h) — 355; 356; 129 mm*h
Allergic Conjunctivitis
Primary: Ocular Itching — 0.4; 1.9; 0.4; 0.5 Units on a scale
Sedation
Primary: Respiratory Depression (Sub-clinical and Clinical Signs) — 0.4; 0.6 percentage of participants
Non Small Cell Lung Cancer · Lung Cancer
Primary: Progression-Free Survival (PFS) in the Overall Population — 17.6; 11.9 weeks
Arthritis, Rheumatoid
Primary: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Treatment-related Adverse Events…
HIV Infections
Primary: Treatment Response at Week 48 — 126; 124; 250; 126 Patients — p=0.684
Hot Flashes
Primary: Percent Change in Frequency of Hot Flashes Over Time — -77.2; -51.8; -53.8; -67.0 Percent change from baseline
Post-Menopausal Osteoporosis · Post-Menopausal Osteopenia
Primary: Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms. — -1.28; -1.22 percentage change in BMD — p=<0.05
Non-Small-Cell Lung Carcinoma
Primary: Overall Survival (OS) — 8.5; 7.8 Months
Conjunctivitis, Allergic
Primary: Ocular Itching — 0.5; 1.9; 0.6; 0.8 Units on a scale
Carcinoma
Primary: Number of Participants With Adverse Events — 12; 5; 7; 0 participants
Metabolic Syndrome · Insulin Resistance
Primary: Adipose Tissue Capillary Sprout Formation — 143.5; 122.1 number of capillary sprouts
Thyroid Cancer
Primary: Progression-Free Survival(PFS) — 30.5; 19.2 Months
Fall Prevention
Primary: Participants With at Least One Fall — 11; 5 participants
Dental Caries
Primary: Percentage of Restorations Scoring Alpha — 100; 96 percentage of Alpha scores — p=0.05